The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome
The study aimed to investigate the triglycerides to HDL-cholesterol ratio (Tg/HDL) and the interaction of this ratio with insulin resistance (IR) and insulin secretion indices, with the levels of interleukin - 1(IL-1), interleukin-6 (Il-6), and tumour necrotic factor-α (TNF-α) in sera among patients...
Gespeichert in:
| Veröffentlicht in: | Journal of Biomedical & Clinical Research 2021-12, Vol.14 (2), p.162-168 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 168 |
|---|---|
| container_issue | 2 |
| container_start_page | 162 |
| container_title | Journal of Biomedical & Clinical Research |
| container_volume | 14 |
| creator | Ganeva, Silviya S. Rayanova, Ginka H. Todorova, Katya N. Lukanov, Tzvetan H. Blazheva, Svetla O. |
| description | The study aimed to investigate the triglycerides to HDL-cholesterol ratio (Tg/HDL) and the interaction of this ratio with insulin resistance (IR) and insulin secretion indices, with the levels of interleukin - 1(IL-1), interleukin-6 (Il-6), and tumour necrotic factor-α (TNF-α) in sera among patients with metabolic syndrome (MS). A prospective, cross-sectional, comparative study was conducted on 45 patients with MS without data for hyperglycemia and 21 metabolically healthy non-obese controls. The levels of fasting and postprandial glucose, immunoreactive insulin (IRI), total cholesterol, triglycerides (Tg), IL-1, IL-6, and TNF-α were measured in all the participants. We calculated the LDL cholesterol levels, Tg/HDL ratio, homeostatic model of insulin resistance (HOMA-IR), and the homeostatic model of β-cell function (HOMA-b). Patients with MS had higher BMI (38.73±1.84 vs. 24.32±2.71 kg/m2; р |
| doi_str_mv | 10.2478/jbcr-2021-0012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2478_jbcr_2021_0012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3156243218</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1602-9e360c10be4bcf0b7a502a499dd2ab0f045f81627236b0be2d14d8a48fe9248d3</originalsourceid><addsrcrecordid>eNptUU1r20AQFaWFhjTXngdyVrpfliXIpahtEnBosd2zGO2O7E0UbTorJfg35U92hQPNoad5MO-9-XhZ9lmKC2WW5Ze71nKuhJK5EFK9y06kljqvxEK_f4M_Zmcx-lYobbQoi-Ike9nuCdahJwgdbNnv-oMl9o5gDHD9bQX1PjXjSBx6WOPoA_gBNsQIGAGh7v3gLfawmZjDDkeCW-R7YugCQ43sfHjCaKceGdY-3gMODm6GOCUhrCn6OOJgaXb9lexpGCM8-3EPtzRiG3pvYXMYHIcH-pR96LCPdPZaT7PfP75v6-t89fPqpv66yq0shMor0oWwUrRkWtuJdokLodBUlXMKW9EJs-hKWail0kWbWMpJ40o0ZUeVMqXTp9n50feRw58pHd_chYmHNLLRclEoo5UsE-viyLIcYmTqmkf2D8iHRopmzqSZM2nmTJo5kyS4PAqesU__dLTj6ZDAP_f_C6VRaVv9Fw_TlRk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3156243218</pqid></control><display><type>article</type><title>The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome</title><source>De Gruyter Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Ganeva, Silviya S. ; Rayanova, Ginka H. ; Todorova, Katya N. ; Lukanov, Tzvetan H. ; Blazheva, Svetla O.</creator><creatorcontrib>Ganeva, Silviya S. ; Rayanova, Ginka H. ; Todorova, Katya N. ; Lukanov, Tzvetan H. ; Blazheva, Svetla O.</creatorcontrib><description><![CDATA[The study aimed to investigate the triglycerides to HDL-cholesterol ratio (Tg/HDL) and the interaction of this ratio with insulin resistance (IR) and insulin secretion indices, with the levels of interleukin - 1(IL-1), interleukin-6 (Il-6), and tumour necrotic factor-α (TNF-α) in sera among patients with metabolic syndrome (MS). A prospective, cross-sectional, comparative study was conducted on 45 patients with MS without data for hyperglycemia and 21 metabolically healthy non-obese controls. The levels of fasting and postprandial glucose, immunoreactive insulin (IRI), total cholesterol, triglycerides (Tg), IL-1, IL-6, and TNF-α were measured in all the participants. We calculated the LDL cholesterol levels, Tg/HDL ratio, homeostatic model of insulin resistance (HOMA-IR), and the homeostatic model of β-cell function (HOMA-b). Patients with MS had higher BMI (38.73±1.84 vs. 24.32±2.71 kg/m2; р<0.05) and waist circumference (115.56 ±4.7 vs. 81.1±8.4cm; р<0.05) than non-obese controls. The same patients had higher LDL cholesterol levels (3.42±0.3 vs. 2.63±0.66 mmol/l; р<0.05) and Tg (1.59±0.22 vs. 1.08±0.31mmol/l; р<0.05), as well as lower levels of HDL-cholesterol (1.03±0.09 vs. 1.27 ± 0.24mmol/l; р<0.05) compared to the controls. The Tg/HDL ratio was 2.03±0.87 among the patients with MS and 0.88±0.27 in controls; р<0.05. The plasma levels of basal IRI (19.32±3.22 mIU/l vs. 9.13±0.73mIU/l; р<0.05), HOMA-IR (4.02 vs. 1.97; р<0.05) and HOMA-b (258.77±57.76 vs. 183.31±17.52; р<0.05) were significantly higher in the MS group. The same patients with MS had higher concentrations of IL-1 (18.37±4.28pg/ml vs. 7.12±1.74pg/ml; p<0.05), IL-6 (1.01±0.3pg/ml vs. 0.1±0.3pg/ml; р<0.05) and TNF-α (2.13±1.43 pg/ml vs. 1.82±0.94pg/ml; р=0.24) too. Positive correlations between the levels of IL-1 and Tg/HDL ratio (r= 0.46; p=0.008), IL-1 and HOMA-%В (r=0.47; p=0.005) were found. The Tg/HDL ratio is a potential, cheap and available surrogate marker for screening for cardiovascular risk and insulin resistance in patients with MS in clinical practice.]]></description><identifier>ISSN: 1313-9053</identifier><identifier>ISSN: 1313-6917</identifier><identifier>EISSN: 1313-9053</identifier><identifier>DOI: 10.2478/jbcr-2021-0012</identifier><language>eng</language><publisher>Pleven: Sciendo</publisher><subject>atherogenic index ; Cholesterol ; Cytokines ; High density lipoprotein ; Insulin resistance ; Low density lipoprotein ; Metabolic syndrome ; Triglycerides</subject><ispartof>Journal of Biomedical & Clinical Research, 2021-12, Vol.14 (2), p.162-168</ispartof><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1602-9e360c10be4bcf0b7a502a499dd2ab0f045f81627236b0be2d14d8a48fe9248d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://sciendo.com/pdf/10.2478/jbcr-2021-0012$$EPDF$$P50$$Gwalterdegruyter$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://sciendo.com/article/10.2478/jbcr-2021-0012$$EHTML$$P50$$Gwalterdegruyter$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,27901,27902,75906,75907</link.rule.ids></links><search><creatorcontrib>Ganeva, Silviya S.</creatorcontrib><creatorcontrib>Rayanova, Ginka H.</creatorcontrib><creatorcontrib>Todorova, Katya N.</creatorcontrib><creatorcontrib>Lukanov, Tzvetan H.</creatorcontrib><creatorcontrib>Blazheva, Svetla O.</creatorcontrib><title>The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome</title><title>Journal of Biomedical & Clinical Research</title><description><![CDATA[The study aimed to investigate the triglycerides to HDL-cholesterol ratio (Tg/HDL) and the interaction of this ratio with insulin resistance (IR) and insulin secretion indices, with the levels of interleukin - 1(IL-1), interleukin-6 (Il-6), and tumour necrotic factor-α (TNF-α) in sera among patients with metabolic syndrome (MS). A prospective, cross-sectional, comparative study was conducted on 45 patients with MS without data for hyperglycemia and 21 metabolically healthy non-obese controls. The levels of fasting and postprandial glucose, immunoreactive insulin (IRI), total cholesterol, triglycerides (Tg), IL-1, IL-6, and TNF-α were measured in all the participants. We calculated the LDL cholesterol levels, Tg/HDL ratio, homeostatic model of insulin resistance (HOMA-IR), and the homeostatic model of β-cell function (HOMA-b). Patients with MS had higher BMI (38.73±1.84 vs. 24.32±2.71 kg/m2; р<0.05) and waist circumference (115.56 ±4.7 vs. 81.1±8.4cm; р<0.05) than non-obese controls. The same patients had higher LDL cholesterol levels (3.42±0.3 vs. 2.63±0.66 mmol/l; р<0.05) and Tg (1.59±0.22 vs. 1.08±0.31mmol/l; р<0.05), as well as lower levels of HDL-cholesterol (1.03±0.09 vs. 1.27 ± 0.24mmol/l; р<0.05) compared to the controls. The Tg/HDL ratio was 2.03±0.87 among the patients with MS and 0.88±0.27 in controls; р<0.05. The plasma levels of basal IRI (19.32±3.22 mIU/l vs. 9.13±0.73mIU/l; р<0.05), HOMA-IR (4.02 vs. 1.97; р<0.05) and HOMA-b (258.77±57.76 vs. 183.31±17.52; р<0.05) were significantly higher in the MS group. The same patients with MS had higher concentrations of IL-1 (18.37±4.28pg/ml vs. 7.12±1.74pg/ml; p<0.05), IL-6 (1.01±0.3pg/ml vs. 0.1±0.3pg/ml; р<0.05) and TNF-α (2.13±1.43 pg/ml vs. 1.82±0.94pg/ml; р=0.24) too. Positive correlations between the levels of IL-1 and Tg/HDL ratio (r= 0.46; p=0.008), IL-1 and HOMA-%В (r=0.47; p=0.005) were found. The Tg/HDL ratio is a potential, cheap and available surrogate marker for screening for cardiovascular risk and insulin resistance in patients with MS in clinical practice.]]></description><subject>atherogenic index</subject><subject>Cholesterol</subject><subject>Cytokines</subject><subject>High density lipoprotein</subject><subject>Insulin resistance</subject><subject>Low density lipoprotein</subject><subject>Metabolic syndrome</subject><subject>Triglycerides</subject><issn>1313-9053</issn><issn>1313-6917</issn><issn>1313-9053</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptUU1r20AQFaWFhjTXngdyVrpfliXIpahtEnBosd2zGO2O7E0UbTorJfg35U92hQPNoad5MO-9-XhZ9lmKC2WW5Ze71nKuhJK5EFK9y06kljqvxEK_f4M_Zmcx-lYobbQoi-Ike9nuCdahJwgdbNnv-oMl9o5gDHD9bQX1PjXjSBx6WOPoA_gBNsQIGAGh7v3gLfawmZjDDkeCW-R7YugCQ43sfHjCaKceGdY-3gMODm6GOCUhrCn6OOJgaXb9lexpGCM8-3EPtzRiG3pvYXMYHIcH-pR96LCPdPZaT7PfP75v6-t89fPqpv66yq0shMor0oWwUrRkWtuJdokLodBUlXMKW9EJs-hKWail0kWbWMpJ40o0ZUeVMqXTp9n50feRw58pHd_chYmHNLLRclEoo5UsE-viyLIcYmTqmkf2D8iHRopmzqSZM2nmTJo5kyS4PAqesU__dLTj6ZDAP_f_C6VRaVv9Fw_TlRk</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Ganeva, Silviya S.</creator><creator>Rayanova, Ginka H.</creator><creator>Todorova, Katya N.</creator><creator>Lukanov, Tzvetan H.</creator><creator>Blazheva, Svetla O.</creator><general>Sciendo</general><general>De Gruyter Poland</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20211201</creationdate><title>The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome</title><author>Ganeva, Silviya S. ; Rayanova, Ginka H. ; Todorova, Katya N. ; Lukanov, Tzvetan H. ; Blazheva, Svetla O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1602-9e360c10be4bcf0b7a502a499dd2ab0f045f81627236b0be2d14d8a48fe9248d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>atherogenic index</topic><topic>Cholesterol</topic><topic>Cytokines</topic><topic>High density lipoprotein</topic><topic>Insulin resistance</topic><topic>Low density lipoprotein</topic><topic>Metabolic syndrome</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ganeva, Silviya S.</creatorcontrib><creatorcontrib>Rayanova, Ginka H.</creatorcontrib><creatorcontrib>Todorova, Katya N.</creatorcontrib><creatorcontrib>Lukanov, Tzvetan H.</creatorcontrib><creatorcontrib>Blazheva, Svetla O.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of Biomedical & Clinical Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ganeva, Silviya S.</au><au>Rayanova, Ginka H.</au><au>Todorova, Katya N.</au><au>Lukanov, Tzvetan H.</au><au>Blazheva, Svetla O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome</atitle><jtitle>Journal of Biomedical & Clinical Research</jtitle><date>2021-12-01</date><risdate>2021</risdate><volume>14</volume><issue>2</issue><spage>162</spage><epage>168</epage><pages>162-168</pages><issn>1313-9053</issn><issn>1313-6917</issn><eissn>1313-9053</eissn><abstract><![CDATA[The study aimed to investigate the triglycerides to HDL-cholesterol ratio (Tg/HDL) and the interaction of this ratio with insulin resistance (IR) and insulin secretion indices, with the levels of interleukin - 1(IL-1), interleukin-6 (Il-6), and tumour necrotic factor-α (TNF-α) in sera among patients with metabolic syndrome (MS). A prospective, cross-sectional, comparative study was conducted on 45 patients with MS without data for hyperglycemia and 21 metabolically healthy non-obese controls. The levels of fasting and postprandial glucose, immunoreactive insulin (IRI), total cholesterol, triglycerides (Tg), IL-1, IL-6, and TNF-α were measured in all the participants. We calculated the LDL cholesterol levels, Tg/HDL ratio, homeostatic model of insulin resistance (HOMA-IR), and the homeostatic model of β-cell function (HOMA-b). Patients with MS had higher BMI (38.73±1.84 vs. 24.32±2.71 kg/m2; р<0.05) and waist circumference (115.56 ±4.7 vs. 81.1±8.4cm; р<0.05) than non-obese controls. The same patients had higher LDL cholesterol levels (3.42±0.3 vs. 2.63±0.66 mmol/l; р<0.05) and Tg (1.59±0.22 vs. 1.08±0.31mmol/l; р<0.05), as well as lower levels of HDL-cholesterol (1.03±0.09 vs. 1.27 ± 0.24mmol/l; р<0.05) compared to the controls. The Tg/HDL ratio was 2.03±0.87 among the patients with MS and 0.88±0.27 in controls; р<0.05. The plasma levels of basal IRI (19.32±3.22 mIU/l vs. 9.13±0.73mIU/l; р<0.05), HOMA-IR (4.02 vs. 1.97; р<0.05) and HOMA-b (258.77±57.76 vs. 183.31±17.52; р<0.05) were significantly higher in the MS group. The same patients with MS had higher concentrations of IL-1 (18.37±4.28pg/ml vs. 7.12±1.74pg/ml; p<0.05), IL-6 (1.01±0.3pg/ml vs. 0.1±0.3pg/ml; р<0.05) and TNF-α (2.13±1.43 pg/ml vs. 1.82±0.94pg/ml; р=0.24) too. Positive correlations between the levels of IL-1 and Tg/HDL ratio (r= 0.46; p=0.008), IL-1 and HOMA-%В (r=0.47; p=0.005) were found. The Tg/HDL ratio is a potential, cheap and available surrogate marker for screening for cardiovascular risk and insulin resistance in patients with MS in clinical practice.]]></abstract><cop>Pleven</cop><pub>Sciendo</pub><doi>10.2478/jbcr-2021-0012</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1313-9053 |
| ispartof | Journal of Biomedical & Clinical Research, 2021-12, Vol.14 (2), p.162-168 |
| issn | 1313-9053 1313-6917 1313-9053 |
| language | eng |
| recordid | cdi_crossref_primary_10_2478_jbcr_2021_0012 |
| source | De Gruyter Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | atherogenic index Cholesterol Cytokines High density lipoprotein Insulin resistance Low density lipoprotein Metabolic syndrome Triglycerides |
| title | The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T12%3A21%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20Triglyceride%20to%20HDL%20Cholesterol%20Ratio%20in%20Sera%20as%20a%20Clinical%20Surrogate%20Marker%20for%20Cardiovascular%20Risk%20and%20Insulin%20Resistance%20in%20Patients%20with%20Metabolic%20Syndrome&rft.jtitle=Journal%20of%20Biomedical%20&%20Clinical%20Research&rft.au=Ganeva,%20Silviya%20S.&rft.date=2021-12-01&rft.volume=14&rft.issue=2&rft.spage=162&rft.epage=168&rft.pages=162-168&rft.issn=1313-9053&rft.eissn=1313-9053&rft_id=info:doi/10.2478/jbcr-2021-0012&rft_dat=%3Cproquest_cross%3E3156243218%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3156243218&rft_id=info:pmid/&rfr_iscdi=true |